PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6060人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254936, encodeId=4f781254936e9, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=专访迈博斯CEO钱雪明：我们在做，全球pH依赖性结合PD-L1抗体, objectType=article, longId=115154, objectId=e6ea11515442, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6ea11515442, replyNumber=0, likeNumber=100, createdTime=2017-10-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6ea11515442, moduleTitle=专访迈博斯CEO钱雪明：我们在做，全球pH依赖性结合PD-L1抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6ea11515442)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254935, encodeId=ccdb125493544, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=FDA大范围叫停PD-1/PD-L1用于血液肿瘤的临床研究, objectType=article, longId=114012, objectId=5fd011401236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd011401236, replyNumber=0, likeNumber=57, createdTime=2017-09-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd011401236, moduleTitle=FDA大范围叫停PD-1/PD-L1用于血液肿瘤的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd011401236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254934, encodeId=44c112549347c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=三家国内PD-1/PD-L1获批临床肿瘤免疫火热患者招募难？, objectType=article, longId=113727, objectId=cced113e27f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cced113e27f3, replyNumber=0, likeNumber=78, createdTime=2017-09-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cced113e27f3, moduleTitle=三家国内PD-1/PD-L1获批临床肿瘤免疫火热患者招募难？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cced113e27f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254933, encodeId=44831254933c3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, objectType=article, longId=112313, objectId=3530112313d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3530112313d7, replyNumber=0, likeNumber=61, createdTime=2017-09-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3530112313d7, moduleTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3530112313d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254932, encodeId=20f012549324e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：黑色素瘤治疗期间PD-L1表达改变可以预测PD-1治疗反应, objectType=article, longId=112126, objectId=95fc11212692, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95fc11212692, replyNumber=0, likeNumber=59, createdTime=2017-09-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95fc11212692, moduleTitle=CLIN CANCER RES：黑色素瘤治疗期间PD-L1表达改变可以预测PD-1治疗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95fc11212692)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254931, encodeId=d07512549319f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：黑色素瘤PD-L1表达：不同免疫组化抗体间的比较, objectType=article, longId=111292, objectId=a2f6111292d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2f6111292d7, replyNumber=0, likeNumber=69, createdTime=2017-08-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2f6111292d7, moduleTitle=CLIN CANCER RES：黑色素瘤PD-L1表达：不同免疫组化抗体间的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2f6111292d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254930, encodeId=2dbb12549304d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：派姆单抗治疗PD-L1阳性鼻咽癌患者的安全性及抗肿瘤活性研究, objectType=article, longId=111067, objectId=776311106e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776311106e61, replyNumber=0, likeNumber=66, createdTime=2017-08-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776311106e61, moduleTitle=JCO：派姆单抗治疗PD-L1阳性鼻咽癌患者的安全性及抗肿瘤活性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=776311106e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254929, encodeId=971c1254929b0, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature：免疫疗法关键靶点PD-L1竟有不为人知的“帮手”, objectType=article, longId=109181, objectId=1a3310918136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a3310918136, replyNumber=0, likeNumber=58, createdTime=2017-08-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a3310918136, moduleTitle=Nature：免疫疗法关键靶点PD-L1竟有不为人知的“帮手”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a3310918136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254928, encodeId=3187125492893, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Ann Oncol：抗PD-1/PD-L1治疗期间复发和/或转移性HNSCC患者的超表达, objectType=article, longId=108788, objectId=f369108e888d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f369108e888d, replyNumber=0, likeNumber=0, createdTime=2017-08-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f369108e888d, moduleTitle=Ann Oncol：抗PD-1/PD-L1治疗期间复发和/或转移性HNSCC患者的超表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f369108e888d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254927, encodeId=32f9125492e78, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1免疫疗法Durvalumab治疗NSCLC喜获FDA突破性药物资格, objectType=article, longId=108460, objectId=27ae108460ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27ae108460ec, replyNumber=0, likeNumber=106, createdTime=2017-08-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27ae108460ec, moduleTitle=PD-L1免疫疗法Durvalumab治疗NSCLC喜获FDA突破性药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27ae108460ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254926, encodeId=5927125492625, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Oncotarget：PD-L1的表达状态和CD8+肿瘤浸润T细胞有作为口咽鳞状细胞癌预后改善标志物的潜力, objectType=article, longId=106869, objectId=21c4106869b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21c4106869b5, replyNumber=0, likeNumber=0, createdTime=2017-07-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21c4106869b5, moduleTitle=Oncotarget：PD-L1的表达状态和CD8+肿瘤浸润T细胞有作为口咽鳞状细胞癌预后改善标志物的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21c4106869b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254925, encodeId=b7ce125492509, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=国内自然全长、全人源抗PD-L1单克隆抗体获CFDA临床试验批件, objectType=article, longId=106671, objectId=9fb41066e1c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb41066e1c5, replyNumber=0, likeNumber=54, createdTime=2017-07-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb41066e1c5, moduleTitle=国内自然全长、全人源抗PD-L1单克隆抗体获CFDA临床试验批件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb41066e1c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254924, encodeId=0ad1125492400, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=SCI REP：脑胶质瘤患者PD-L1表达的预后意义！, objectType=article, longId=103444, objectId=5e6e10344497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6e10344497, replyNumber=0, likeNumber=107, createdTime=2017-06-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6e10344497, moduleTitle=SCI REP：脑胶质瘤患者PD-L1表达的预后意义！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6e10344497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254923, encodeId=db911254923b6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：Atezolizumab一线治疗PD-L1阳性晚期NSCLC有效，OS接近2年, objectType=article, longId=102582, objectId=702f102582ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=702f102582ee, replyNumber=0, likeNumber=55, createdTime=2017-06-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=702f102582ee, moduleTitle=J Clin Oncol：Atezolizumab一线治疗PD-L1阳性晚期NSCLC有效，OS接近2年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=702f102582ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254922, encodeId=4aaa125492202, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：Atezolizumab一线治疗PD-L1表达的晚期非小细胞肺癌的疗效研究（BIRCH研究）, objectType=article, longId=102133, objectId=14f0102133d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f0102133d8, replyNumber=0, likeNumber=67, createdTime=2017-06-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f0102133d8, moduleTitle=JCO：Atezolizumab一线治疗PD-L1表达的晚期非小细胞肺癌的疗效研究（BIRCH研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f0102133d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254921, encodeId=170a12549215f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001), objectType=article, longId=100336, objectId=ff47100336ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff47100336ed, replyNumber=0, likeNumber=65, createdTime=2017-06-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff47100336ed, moduleTitle=Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff47100336ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254920, encodeId=134012549207f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cell Report：新型佐剂增强肿瘤疫苗反应，提高阻断PD-1/PD-L1疗法成功率, objectType=article, longId=100222, objectId=0d7010022290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d7010022290, replyNumber=0, likeNumber=59, createdTime=2017-06-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d7010022290, moduleTitle=Cell Report：新型佐剂增强肿瘤疫苗反应，提高阻断PD-1/PD-L1疗法成功率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d7010022290)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254919, encodeId=54db1254919ec, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature：PD-1/ PD-L1抗体另一条不为人知的抗癌方式, objectType=article, longId=99342, objectId=27dd993421f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27dd993421f, replyNumber=0, likeNumber=56, createdTime=2017-05-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27dd993421f, moduleTitle=Nature：PD-1/ PD-L1抗体另一条不为人知的抗癌方式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27dd993421f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254918, encodeId=c5d4125491838, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Chest：非小细胞肺癌患者采用PD-1和PD-L1抑制剂肺炎发生率有何差异？, objectType=article, longId=98586, objectId=24189858651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24189858651, replyNumber=0, likeNumber=57, createdTime=2017-05-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24189858651, moduleTitle=Chest：非小细胞肺癌患者采用PD-1和PD-L1抑制剂肺炎发生率有何差异？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24189858651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254917, encodeId=ea1d125491eb7, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, objectType=article, longId=101079, objectId=78e61010e913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61010e913, replyNumber=0, likeNumber=62, createdTime=2017-05-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61010e913, moduleTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61010e913)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

专访迈博斯CEO钱雪明：我们在做，全球pH依赖性结合PD-L1抗体

2017-10-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

FDA大范围叫停PD-1/PD-L1用于血液肿瘤的临床研究

2017-09-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

三家国内PD-1/PD-L1获批临床肿瘤免疫火热患者招募难？

2017-09-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关

2017-09-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：黑色素瘤治疗期间PD-L1表达改变可以预测PD-1治疗反应

2017-09-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：黑色素瘤PD-L1表达：不同免疫组化抗体间的比较

2017-08-31

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：派姆单抗治疗PD-L1阳性鼻咽癌患者的安全性及抗肿瘤活性研究

2017-08-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature：免疫疗法关键靶点PD-L1竟有不为人知的“帮手”

2017-08-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Ann Oncol：抗PD-1/PD-L1治疗期间复发和/或转移性HNSCC患者的超表达

2017-08-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1免疫疗法Durvalumab治疗NSCLC喜获FDA突破性药物资格

2017-08-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Oncotarget：PD-L1的表达状态和CD8+肿瘤浸润T细胞有作为口咽鳞状细胞癌预后改善标志物的潜力

2017-07-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

国内自然全长、全人源抗PD-L1单克隆抗体获CFDA临床试验批件

2017-07-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

SCI REP：脑胶质瘤患者PD-L1表达的预后意义！

2017-06-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：Atezolizumab一线治疗PD-L1阳性晚期NSCLC有效，OS接近2年

2017-06-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：Atezolizumab一线治疗PD-L1表达的晚期非小细胞肺癌的疗效研究（BIRCH研究）

2017-06-17

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Lancet Oncol：放疗与PD-L1抑制剂：携手共抗肺癌(KEYNOTE-001)

2017-06-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cell Report：新型佐剂增强肿瘤疫苗反应，提高阻断PD-1/PD-L1疗法成功率

2017-06-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature：PD-1/ PD-L1抗体另一条不为人知的抗癌方式

2017-05-24

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Chest：非小细胞肺癌患者采用PD-1和PD-L1抑制剂肺炎发生率有何差异？

2017-05-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准

2017-05-12

科室
- - 订阅+
  - 更多科室
工具
服务